BioSpace News Archive

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced positive results in its Phase 2 study of PL9643 for the treatment of dry eye disease (DED)

To provide quick, effective disinfection against SARS-CoV-2, the coronavirus that causes the COVID-19 disease, Xenex Disinfection Services , the world leader in UV disinfection for healthcare facilities, today announced the availability of LightStrike6 , the highly-anticipated new version of its patented Germ-Zapping Robots. This press release features multimedia. View the full release here: https://www.businesswire.co

vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio, a newly-formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NI

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial evaluating the Company’s lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM). The sixth cohort of the ReSP

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program manageme

Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, announced today that Ivanetta Davis Samuels is joining its Board of Directors, effective December 15, 2020.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its NanoMetalene® surface technology with amended indications.

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purchase Agreement”), resulting in aggregate proceeds of up to $20.7 million in common stock and warrant investment by funds affiliated with an institutional investor.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to